A Report That Describes Different Types of Biomarkers and Their Discovery Using Various ''-omics'' Technologies Such as Proteomics and Metabolomics.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c34742) has announced the addition of Jain Pharmabiotech's Biomarkers - Technologies, Markets and Companies to their offering. This report follows the broad definition of a biomarker biomarker /bio·mark·er/ (bi´o-mahr?ker) 1. a biological molecule used as a marker for a substance or process of interest. 2. tumor marker. bi·o·mark·er n. 1. as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic path·o·gen·ic or path·o·ge·net·ic adj. 1. Having the capability to cause disease. 2. Producing disease. 3. Relating to pathogenesis. processes as well as pharmacological Pharmacological Referring to therapy that relies on drugs. Mentioned in: Pain Management pharmacological, pharmacologic pertaining to pharmacology. responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century. This report describes different types of biomarkers and their discovery using various "-omics" technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker. Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine  The external links in this article or section may require cleanup to comply with Wikipedia's content policies. . Biomarkers play a role in use of
pharmacogenetics Pharmacogenetics DefinitionPharmacogenetics is the study of how the actions of and reactions to drugs vary with the patient's genes. Description , pharmacogenomics Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. and pharmacoproteomics for development of personalized medicine. Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed. Biomarker markets are estimated from 2005 to 2015 according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed. A large number of companies with varying technical backgrounds are involved in biomarkers and 164 of these are profiled in the report. These also include major pharmaceutical companies. There is tabulation tab·u·late tr.v. tab·u·lat·ed, tab·u·lat·ing, tab·u·lates 1. To arrange in tabular form; condense and list. 2. To cut or form with a plane surface. adj. Having a plane surface. of 285 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies. The report is supplemented by 300 references, 32 tables and 7 figures. Contents Include:- Executive Summary 1. Introduction 2. Technologies for Discovery of Biomarkers 3. Biomarkers and Molecular Diagnostics 4. Biomarkers for Drug Discovery & Development 5. Role of Biomarkers in Various Diseases 6. Biomarkers in Cancer 7. Biomarkers of Neurological Disorders 8. Biomarkers of Cardiovascular Disorders 9. Biomarkers & Personalized Medicine 10. Regulatory issues 11. Markets for Biomarkers 12. Companies 13. References Tables Figures For more information visit http://www.researchandmarkets.com/reports/c34742 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion